Novel approaches for vaccine development

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592 · see citing works

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119 · see citing works

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32661-1 · Cited by 4,616 · see citing works

Direct Gene Transfer into Mouse Muscle in Vivo

Wolff, J. A., Malone, R. W., Williams, P., Chong, W., Acsadi, G., Jani, A., & Felgner, P. L. (1990) · Science · doi:10.1126/science.1690918 · Cited by 4,173 · cited 3× · see citing works

Toll-like receptor control of the adaptive immune responses

Iwasaki, A., & Medzhitov, R. M. (2004) · Nature Immunology · doi:10.1038/ni1112 · Cited by 4,166 · see citing works

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,237 · cited 4× · see citing works

Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis

Adams, D., Gonzalez-Duarte, A., O’Riordan, W. D., Yang, C.-C., Ueda, M., Kristen, A. V., Tournev, I., Schmidt, H. H., Coelho, T., Berk, J. L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716153 · Cited by 3,047 · see citing works

Suppression of RNA Recognition by Toll-like Receptors: The Impact of Nucleoside Modification and the Evolutionary Origin of RNA

Karikó, K., Buckstein, M., Ni, H., & Weissman, D. (2005) · Immunity · doi:10.1016/j.immuni.2005.06.008 · Cited by 2,728 · see citing works

mRNA-based therapeutics--developing a new class of drugs

Sahin, U., Karikó, K., & Türeci, Ö. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4278 · Cited by 2,474 · see citing works

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Folegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419 · see citing works

Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study

Shi, T., McAllister, D., O’Brien, K. L., Simões, E. A. F., Madhi, S. A., Gessner, B. D., Polack, F. P., Balsells, E., Acácio, S., Aguayo, C., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30938-8 · Cited by 2,382 · see citing works

Heterologous Protection Against Influenza by Injection of DNA Encoding a Viral Protein

Ulmer, J. B., Donnelly, J., Parker, S. E., Rhodes, G. H., Felgner, P. L., Dwarki, V., Gromkowski, S. H., Deck, R. R., DeWitt, C. M., Friedman, A., et al. (1993) · Science · doi:10.1126/science.8456302 · Cited by 2,318 · see citing works

SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness

Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., et al. (2020) · Nature · doi:10.1038/s41586-020-2622-0 · Cited by 1,615 · see citing works

Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report

Mulligan, M. J., Lyke, K. E., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Raabe, V., Bailey, R., Swanson, K. A., et al. (2020) · doi:10.1101/2020.06.30.20142570 · Cited by 1,569 · see citing works

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults

Anderson, E. J., Rouphael, N. G., Widge, A. T., Jackson, L. A., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2028436 · Cited by 1,523 · see citing works

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial

Zhu, F.-C., Li, Y.-H., Guan, X.-H., Hou, L.-H., Wang, W.-J., Li, J.-X., Wu, S.-P., Wang, B.-S., Wang, Z., Wang, L., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31208-3 · Cited by 1,382 · see citing works

Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo

Jayaraman, M., Ansell, S. M., Mui, B. L., Tam, Y. K., Chen, J., Du, X., Butler, D., Eltepu, L., Matsuda, S., Narayanannair, J. K., et al. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201203263 · Cited by 1,267 · see citing works

Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms

Akinc, A., Querbes, W., De, S., Qin, J., Frank-Kamenetsky, M., Jayaprakash, K. N., Jayaraman, M., Rajeev, K. G., Cantley, W. L., Dorkin, J. R., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.85 · Cited by 1,261 · see citing works

Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial

Zhu, F.-C., Guan, X.-H., Li, Y.-H., Huang, J.-Y., Jiang, T., Hou, L.-H., Li, J.-X., Yang, B.-F., Wang, L., Wang, W.-J., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31605-6 · Cited by 1,225 · see citing works

Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine

Sadoff, J., Le Gars, M., Shukarev, G., Heerwegh, D., Truyers, C., de Groot, A. M., Stoop, J., Tete, S., Van Damme, W., Leroux-Roels, I., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2034201 · Cited by 1,208 · see citing works

Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates

Corbett, K. S., Flynn, B., Foulds, K. E., Francica, J. R., Boyoglu-Barnum, S., Werner, A. P., Flach, B., O’Connell, S., Bock, K. W., Minai, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024671 · Cited by 1,066 · see citing works

Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia

Logunov, D. Y., Dolzhikova, I. V., Zubkova, O. V., Tukhvatulin, A. I., Shcheblyakov, D. V., Dzharullaeva, A. S., Grousova, D. M., Erokhova, A. S., Kovyrshina, A. V., Botikov, A. G., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31866-3 · Cited by 1,055 · see citing works

Programming the magnitude and persistence of antibody responses with innate immunity

Kasturi, S. P., Skountzou, I., Albrecht, R. A., Koutsonanos, D., Tang, H., Nakaya, H. I., Ravindran, R., Stewart, S. M., Alam, M. S., Kwissa, M., et al. (2011) · Nature · doi:10.1038/nature09737 · Cited by 970 · see citing works

Functional 5′ UTR mRNA structures in eukaryotic translation regulation and how to find them

Leppek, K., Das, R., & Barna, M. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.103 · Cited by 949 · see citing works

In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium

Rosenfeld, M. A., Yoshimura, K., Trapnell, B. C., Yoneyama, K., Rosenthal, E. R., Dalemans, W., Fukayama, M., Bargon, J., Stier, L. E., Stratford-Perricaudet, L. D., et al. (1992) · Cell · doi:10.1016/0092-8674(92)90213-v · Cited by 930 · see citing works

Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines

Hassett, K. J., Benenato, K. E., Jacquinet, E., Lee, A., Woods, A., Yuzhakov, O., Himansu, S., Deterling, J., Geilich, B. M., Ketova, T., et al. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.01.013 · Cited by 927 · see citing works

ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques

van Doremalen, N., Lambe, T., Spencer, A., Belij-Rammerstorfer, S., Purushotham, J. N., Port, J. R., Avanzato, V. A., Bushmaker, T., Flaxman, A., Ulaszewska, M., et al. (2020) · Nature · doi:10.1038/s41586-020-2608-y · Cited by 914 · see citing works

Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA

Karikó, K., Muramatsu, H., Ludwig, J., & Weissman, D. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr695 · Cited by 898 · see citing works

Beyond binding: antibody effector functions in infectious diseases

Lu, L. L., Suscovich, T. J., Fortune, S. M., & Alter, G. (2017) · Nature reviews. Immunology · doi:10.1038/nri.2017.106 · Cited by 810 · see citing works

Single-Shot Ad26 Vaccine Protects Against SARS-CoV-2 in Rhesus Macaques

Mercado, N. B., Zahn, R., Wegmann, F., Loos, C., Chandrashekar, A., Yu, J., Liu, J., Peter, L., McMahan, K., Tostanoski, L. H., et al. (2020) · Nature · doi:10.1038/s41586-020-2607-z · Cited by 789 · see citing works

Immune Responses to Viral Gene Therapy Vectors

Shirley, J. L., de Jong, Y. P., Terhorst, C., & Herzog, R. W. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.01.001 · Cited by 788 · see citing works

Regulation of mRNA stability in mammalian cells

Guhaniyogi, J., & Brewer, G. (2001) · Gene · doi:10.1016/s0378-1119(01)00350-x · Cited by 729 · see citing works

Nonviral Gene Delivery: Principle, Limitations, and Recent Progress

Al-Dosari, M. S., & Gao, X. (2009) · The AAPS Journal · doi:10.1208/s12248-009-9143-y · Cited by 706 · see citing works

Adenovirus-mediated gene delivery: Potential applications for gene and cell-based therapies in the new era of personalized medicine

Lee, C. S., Bishop, E. S., Zhang, R., Yu, X., Farina, E. M., Yan, S., Zhao, C., Zeng, Z., Shu, Y., Wu, X., et al. (2017) · Genes & Diseases · doi:10.1016/j.gendis.2017.04.001 · Cited by 691 · see citing works

Nonviral delivery of self-amplifying RNA vaccines

Geall, A. J., Verma, A., Otten, G. R., Shaw, C. A., Hekele, A., Banerjee, K., Cu, Y., Beard, C. W., Brito, L. A., Krucker, T., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1209367109 · Cited by 675 · cited 1× · see citing works

Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses

Bahl, K., Senn, J. J., Yuzhakov, O., Bulychev, A., Brito, L. A., Hassett, K. J., Laska, M. E., Smith, M., Almarsson, Ö., Thompson, J., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.035 · Cited by 642 · see citing works

Gold Nanoparticles as a Vaccine Platform: Influence of Size and Shape on Immunological Responses in Vitro and in Vivo

Niikura, K., Matsunaga, T., Suzuki, T., Kobayashi, S., Yamaguchi, H., Orba, Y., Kawaguchi, A., Hasegawa, H., Kajino, K., Ninomiya, T., et al. (2013) · ACS Nano · doi:10.1021/nn3057005 · Cited by 639 · see citing works

Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells

Holtkamp, S., Kreiter, S., Selmi, A., Simon, P., Koslowski, M., Huber, C., Türeci, O., & Sahin, U. (2006) · Blood · doi:10.1182/blood-2006-04-015024 · Cited by 625 · see citing works

A simple technique for the rescue of early region I mutations into infectious human adenovirus type 5

McGrory, W. J., Bautista, D., & Graham, F. L. (1988) · Virology · doi:10.1016/0042-6822(88)90302-9 · Cited by 590 · see citing works

mRNA structure regulates protein expression through changes in functional half-life

Mauger, D. M., Cabral, B. J., Presnyak, V., Su, S. V., Reid, D. W., Goodman, B., Link, K., Khatwani, N., Reynders, J., Moore, M. J., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1908052116 · Cited by 555 · see citing works

Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome

Sharp, F. A., Ruane, D., Claass, B., Creagh, E. M., Harris, J., Malyala, P., Singh, M., O’Hagan, D. T., Pétrilli, V., Tschopp, J., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804897106 · Cited by 536 · see citing works

Comparative Seroprevalence and Immunogenicity of Six Rare Serotype Recombinant Adenovirus Vaccine Vectors from Subgroups B and D

Abbink, P., Lemckert, A. A. C., Ewald, B. A., Lynch, D. M., Denholtz, M., Smits, S., Holterman, L., Damen, I., Vogels, R., Thorner, A. R., et al. (2007) · Journal of Virology · doi:10.1128/jvi.02696-06 · Cited by 503 · see citing works

Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys

Abbink, P., Larocca, R. A., Barrera, R. A. D. L., Bricault, C. A., Moseley, E. T., Boyd, M. B., Kirilova, M., Li, Z., Ng’ang’a, D., Nanayakkara, O., et al. (2016) · Science · doi:10.1126/science.aah6157 · Cited by 498 · see citing works

Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity

Roberts, D. M., Nanda, A., Havenga, M. J. E., Abbink, P., Lynch, D. M., Ewald, B. A., Liu, J., Thorner, A. R., Swanson, P. E., Gorgone, D. A., et al. (2006) · Nature · doi:10.1038/nature04721 · Cited by 490 · see citing works

Biomaterial-assisted targeted modulation of immune cells in cancer treatment

Wang, H., & Mooney, D. J. (2018) · Nature Materials · doi:10.1038/s41563-018-0147-9 · Cited by 471 · see citing works

Structural Analysis Reveals that Toll-like Receptor 7 Is a Dual Receptor for Guanosine and Single-Stranded RNA

Zhang, Z., Ohto, U., Shibata, T., Krayukhina, E., Taoka, M., Yamauchi, Y., Tanji, H., Isobe, T., Uchiyama, S., Miyake, K., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.09.011 · Cited by 461 · see citing works

mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials

Feldman, R. A., Fuhr, R., Smolenov, I., (Mick) Ribeiro, A., Panther, L., Watson, M., Senn, J. J., Smith, M., Almarsson, Ӧ., Pujar, H. S., et al. (2019) · Vaccine · doi:10.1016/j.vaccine.2019.04.074 · Cited by 454 · cited 1× · see citing works

Simply put: Vaccination saves lives

Orenstein, W. A., & Ahmed, R. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1704507114 · Cited by 449 · see citing works

In vivo characterization of the physicochemical properties of polymer-linked TLR agonists that enhance vaccine immunogenicity

Lynn, G. M., Laga, R., Darrah, P. A., Ishizuka, A. S., Balaci, A. J., Dulcey, A. E., Pechar, M., Pola, R., Gerner, M. Y., Yamamoto, A., et al. (2015) · Nature Biotechnology · doi:10.1038/nbt.3371 · Cited by 441 · see citing works

Induction of Potent Neutralizing Antibody Responses by a Designed Protein Nanoparticle Vaccine for Respiratory Syncytial Virus

Marcandalli, J., Fiala, B., Ols, S., Perotti, M., de van der Schueren, W., Snijder, J., Hodge, E. A., Benhaim, M. A., Ravichandran, R., Carter, L. P., et al. (2019) · Cell · doi:10.1016/j.cell.2019.01.046 · Cited by 439 · see citing works

Slow Delivery Immunization Enhances HIV Neutralizing Antibody and Germinal Center Responses via Modulation of Immunodominance

Cirelli, K. M., Carnathan, D. G., Nogal, B., Martin, J. T., Rodriguez, O. L., Upadhyay, A. A., Enemuo, C. A., Gebru, E. H., Choe, Y., Viviano, F., et al. (2019) · Cell · doi:10.1016/j.cell.2019.04.012 · Cited by 433 · see citing works

Efficient Targeting and Activation of Antigen-Presenting Cells In Vivo after Modified mRNA Vaccine Administration in Rhesus Macaques

Liang, F., Lindgren, G., Lin, A., Thompson, E. A., Ols, S., Röhss, J., John, S., Hassett, K., Yuzhakov, O., Bahl, K., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.08.006 · Cited by 395 · see citing works

Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys

Barouch, D. H., O’Brien, K. L., Simmons, N. L., King, S. L., Abbink, P., Maxfield, L. F., Sun, Y.-H., Porte, A. L., Riggs, A. M., Lynch, D. M., et al. (2010) · Nature Medicine · doi:10.1038/nm.2089 · Cited by 384 · see citing works

Return On Investment From Childhood Immunization In Low- And Middle-Income Countries, 2011–20

Ozawa, S., Clark, S. E., Portnoy, A., Grewal, S. K., Brenzel, L., & Walker, D. G. (2016) · Health Affairs · doi:10.1377/hlthaff.2015.1086 · Cited by 378 · see citing works

Tailoring mRNA Vaccine to Balance Innate/Adaptive Immune Response

Linares-Fernández, S., Lacroix, C., Exposito, J.-Y., & Verrier, B. (2020) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.10.002 · Cited by 376 · see citing works

Neutralizing Antibodies to Adenovirus Serotype 5 Vaccine Vectors Are Directed Primarily against the Adenovirus Hexon Protein

Sumida, S. M., Truitt, D. M., Lemckert, A. A. C., Vogels, R., Custers, J. H. H. V., Addo, M. M., Lockman, S., PETER, T. F., Peyerl, F. W., Kishko, M., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.11.7179 · Cited by 369 · see citing works

Improving mRNA-Based Therapeutic Gene Delivery by Expression-Augmenting 3′ UTRs Identified by Cellular Library Screening

Orlandini von Niessen, A. G., Poleganov, M. A., Rechner, C., Plaschke, A., Kranz, L. M., Fesser, S., Diken, M., Löwer, M., Vallazza, B., Beissert, T., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2018.12.011 · Cited by 365 · see citing works

Impact of mRNA chemistry and manufacturing process on innate immune activation

Nelson, J., Sorensen, E. W., Mintri, S., Rabideau, A. E., Zheng, W., Besin, G., Khatwani, N., Su, S. V., Miracco, E. J., Issa, W. J., et al. (2020) · Science Advances · doi:10.1126/sciadv.aaz6893 · Cited by 354 · see citing works

COVID-19 Vaccine Frontrunners and Their Nanotechnology Design

Chung, Y. H., Beiss, V., Fiering, S., & Steinmetz, N. F. (2020) · ACS Nano · doi:10.1021/acsnano.0c07197 · Cited by 341 · see citing works

Recent updates on drug resistance in Mycobacterium tuberculosis

Singh, R. K. B., Dwivedi, S. P., Gaharwar, U. S., Meena, R., Rajamani, P., & Prasad, T. (2019) · Journal of Applied Microbiology · doi:10.1111/jam.14478 · Cited by 340 · see citing works

Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19)

Barouch, D. H., Tomaka, F. L., Wegmann, F., Stieh, D. J., Alter, G., Robb, M. L., Michael, N. L., Peter, L. E., Nkolola, J. P., Borducchi, E. N., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31364-3 · Cited by 337 · see citing works

International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations

Barouch, D. H., Kik, S. V., Weverling, G. J., Dilan, R., King, S. L., Maxfield, L. F., Clark, S., Ng’ang’a, D., Brandariz, K., Abbink, P., et al. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.05.025 · Cited by 305 · see citing works

Inflammasome-activating nanoparticles as modular systems for optimizing vaccine efficacy

Demento, S. L., Eisenbarth, S. C., Foellmer, H. G., Platt, C., Caplan, M. J., Mark Saltzman, W., Mellman, I., Ledizet, M., Fikrig, E., Flavell, R. A., et al. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.03.034 · Cited by 290 · see citing works

Direct Gene Transfer into Nonhuman Primate Myofibers In Vivo

Jiao, S., Williams, P., Berg, R. K., Hodgeman, B. A., Liu, L., Repetto, G. M., & Wolff, J. A. (1992) · Human Gene Therapy · doi:10.1089/hum.1992.3.1-21 · Cited by 283 · see citing works

Multifaceted Effects of Antigen Valency on B Cell Response Composition and Differentiation In Vivo

Kato, Y., Abbott, R. K., Freeman, B. L., Haupt, S., Gröschel, B., Silva, M., Menis, S., Irvine, D. J., Schief, W. R., & Crotty, S. (2020) · Immunity · doi:10.1016/j.immuni.2020.08.001 · Cited by 267 · see citing works

The Mechanism of Naked DNA Uptake and Expression

Wolff, J. A., & Budker, V. G. (2005) · Advances in genetics · doi:10.1016/s0065-2660(05)54001-x · Cited by 260 · see citing works

Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines

Lutz, J., Lazzaro, S., Habbeddine, M., Schmidt, K. E., Baumhof, P., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., Heidenreich, R., et al. (2017) · npj Vaccines · doi:10.1038/s41541-017-0032-6 · Cited by 257 · cited 1× · see citing works

A live-attenuated Zika virus vaccine candidate induces sterilizing immunity in mouse models

Shan, C., Muruato, A. E., Nunes, B. T. D., Luo, H., Xie, X., Medeiros, D. B. D. A., Wakamiya, M., Tesh, R. B., Barrett, A. D. T., Wang, T., et al. (2017) · Nature Medicine · doi:10.1038/nm.4322 · Cited by 255 · see citing works

Vaccine technologies: From whole organisms to rationally designed protein assemblies

Karch, C. P., & Burkhard, P. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.05.001 · Cited by 252 · see citing works

Controlling timing and location in vaccines

Irvine, D. J., Aung, A., & Silva, M. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.019 · Cited by 251 · see citing works

Type I IFN counteracts the induction of antigen-specific immune responses by lipid-based delivery of mRNA vaccines

Pollard, C., Rejman, J., De Haes, W., Verrier, B., Van Gulck, E., Naessens, T., De Smedt, S., Bogaert, P., Grooten, J., Vanham, G., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2012.202 · Cited by 248 · see citing works

Advances in nanomaterial vaccine strategies to address infectious diseases impacting global health

Fries, C. N., Curvino, E. J., Chen, J., Permar, S. R., Fouda, G. G., & Collier, J. H. (2020) · Nature Nanotechnology · doi:10.1038/s41565-020-0739-9 · Cited by 246 · see citing works

Biodegradable Polymeric Nanoparticles for Therapeutic Cancer Treatments

Karlsson, J. E., Vaughan, H. J., & Green, J. J. (2018) · Annual Review of Chemical and Biomolecular Engineering · doi:10.1146/annurev-chembioeng-060817-084055 · Cited by 238 · see citing works

Multi-antigenic human cytomegalovirus mRNA vaccines that elicit potent humoral and cell-mediated immunity

John, S., Yuzhakov, O., Woods, A., Deterling, J., Hassett, K., Shaw, C. A., & Ciaramella, G. (2018) · Vaccine · doi:10.1016/j.vaccine.2018.01.029 · Cited by 229 · see citing works

<scp>RNA</scp> sensors of the innate immune system and their detection of pathogens

Chen, N., Xia, P., Li, S., Zhang, T., Wang, T. T., & Zhu, J. (2017) · IUBMB Life · doi:10.1002/iub.1625 · Cited by 225 · see citing works

Recombinant Adenovirus Serotype 26 (Ad26) and Ad35 Vaccine Vectors Bypass Immunity to Ad5 and Protect Nonhuman Primates against Ebolavirus Challenge

Geisbert, T. W., Bailey, M., Hensley, L. E., Asiedu, C. K., Geisbert, J. B., Stanley, D. A., Honko, A. N., Johnson, J. C., Mulangu, S., Pau, M. G., et al. (2011) · Journal of Virology · doi:10.1128/jvi.02407-10 · Cited by 224 · see citing works

Adenoviral Gene Therapy

Vorburger, S. A., & Hunt, K. K. (2002) · The Oncologist · doi:10.1634/theoncologist.7-1-46 · Cited by 220 · see citing works

Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers

Bernstein, D. I., Reap, E. A., Katen, K., Watson, A., Smith, K., Norberg, P., Olmsted, R. A., Hoeper, A., Morris, J., Negri, S., et al. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.09.135 · Cited by 212 · see citing works

Spontaneous cellular uptake of exogenous messenger RNA in vivo is nucleic acid-specific, saturable and ion dependent

Probst, J., Weide, B., Scheel, B., Pichler, B. J., Hoerr, I., Rammensee, H.-G., & Pascolo, S. (2007) · Gene Therapy · doi:10.1038/sj.gt.3302964 · Cited by 206 · see citing works

Designing biomaterials with immunomodulatory properties for tissue engineering and regenerative medicine

Andorko, J. I., & Jewell, C. M. (2017) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10063 · Cited by 203 · see citing works

Human Clinical Trials of Plasmid DNA Vaccines

Liu, M. A., & Ulmer, J. B. (2005) · Advances in genetics · doi:10.1016/s0065-2660(05)55002-8 · Cited by 198 · see citing works

Development and optimization of an adenovirus production process

Kamen, A., & Henry, O. (2004) · The Journal of Gene Medicine · doi:10.1002/jgm.503 · Cited by 194 · see citing works

Modified mRNA/lipid nanoparticle-based vaccines expressing respiratory syncytial virus F protein variants are immunogenic and protective in rodent models of RSV infection

Espeseth, A. S., Cejas, P. J., Citron, M. P., Wang, D., DiStefano, D. J., Callahan, C., Donnell, G. O., Galli, J. D., Swoyer, R., Touch, S., et al. (2020) · npj Vaccines · doi:10.1038/s41541-020-0163-z · Cited by 190 · see citing works

Enhancing and shaping the immunogenicity of native-like HIV-1 envelope trimers with a two-component protein nanoparticle

Brouwer, P. J. M., Antanasijevic, A., Berndsen, Z. T., Yasmeen, A., Fiala, B., Bijl, T. P. L., Bontjer, I., Bale, J. B., Sheffler, W., Allen, J. D., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12080-1 · Cited by 185 · see citing works

A review of 65 years of human adenovirus seroprevalence

Mennechet, F. J. D., Paris, O., Ouoba, A. R., Arenas, S. S., Sirima, S. B., Dzomo, G. R. T., Diarra, A., Traore, I. T., Kania, D., Eichholz, K., et al. (2019) · Expert Review of Vaccines · doi:10.1080/14760584.2019.1588113 · Cited by 184 · see citing works

Immune Sensing Mechanisms that Discriminate Self from Altered Self and Foreign Nucleic Acids

Bartok, E., & Hartmann, G. (2020) · Immunity · doi:10.1016/j.immuni.2020.06.014 · Cited by 184 · see citing works

Chimpanzee Adenovirus Antibodies in Humans, Sub-Saharan Africa

Xiang, Z., Li, Y., Cun, A., Yang, W. P., Ellenberg, S. S., Switzer, W. M., Kalish, M. L., & Ertl, H. C. J. (2006) · Emerging infectious diseases · doi:10.3201/eid1210.060078 · Cited by 178 · see citing works

Adenovirus-mediated transfer of a recombinant human alpha 1-antitrypsin cDNA to human endothelial cells.

Lemarchand, P., Jaffe, H. A., Danel, C. J., Cid, M. C., Kleinman, H. K., Stratford-Perricaudet, L. D., Perricaudet, M., Pavirani, A., Lecocq, J., & Crystal, R. G. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.14.6482 · Cited by 176 · see citing works

Adjuvant-carrying synthetic vaccine particles augment the immune response to encapsulated antigen and exhibit strong local immune activation without inducing systemic cytokine release

Ilyinskii, P. O., Roy, C. J., O’Neil, C. P., Browning, E., Pittet, L. A., Altreuter, D. H., Alexis, F., Tonti, E., Shi, J., Basto, P. A., et al. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.02.027 · Cited by 174 · see citing works

The global burden of HIV and prospects for control

Pandey, A., & Galvani, A. P. (2019) · The Lancet HIV · doi:10.1016/s2352-3018(19)30230-9 · Cited by 173 · see citing works

mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents

Rauch, S., Roth, N., Schwendt, K., Fotin-Mleczek, M., Mueller, S. O., & Petsch, B. (2021) · npj Vaccines · doi:10.1038/s41541-021-00311-w · Cited by 165 · see citing works

Differential functional effects of biomaterials on dendritic cell maturation

Park, J., & Babensee, J. E. (2012) · Acta Biomaterialia · doi:10.1016/j.actbio.2012.06.006 · Cited by 156 · see citing works

Immunogenicity and protective efficacy induced by self-amplifying mRNA vaccines encoding bacterial antigens

Maruggi, G., Chiarot, E., Giovani, C., Buccato, S., Bonacci, S., Frigimelica, E., Margarit, I., Geall, A., Bensi, G., & Maione, D. (2017) · Vaccine · doi:10.1016/j.vaccine.2016.11.040 · Cited by 149 · see citing works

Viral Vectors for Gene Transfer

Chen, Y. H., Keiser, M. S., & Davidson, B. L. (2018) · Current Protocols in Mouse Biology · doi:10.1002/cpmo.58 · Cited by 146 · see citing works

Adenovirus-Based Vaccines: Comparison of Vectors from Three Species of Adenoviridae

Chen, H., Xiang, Z., Li, Y., Kurupati, R. K., Jia, B., Bian, A., Zhou, D., Hutnick, N. A., Yuan, S., Gray, C., et al. (2010) · Journal of Virology · doi:10.1128/jvi.00450-10 · Cited by 145 · see citing works

The influence of innate and pre‐existing immunity on adenovirus therapy

Zaiss, A. K., Machado, H. B., & Herschman, H. R. (2009) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22328 · Cited by 141 · see citing works

Shaping humoral immunity to vaccines through antigen-displaying nanoparticles

Irvine, D. J., & Read, B. J. (2020) · Current Opinion in Immunology · doi:10.1016/j.coi.2020.01.007 · Cited by 141 · see citing works

Dual TLR agonist nanodiscs as a strong adjuvant system for vaccines and immunotherapy

Kuai, R., Sun, X., Yuan, W., Ochyl, L. J., Xu, Y., Najafabadi, A. H., Scheetz, L. M., Yu, M., Balwani, I., Schwendeman, A. A., et al. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.04.041 · Cited by 138 · see citing works

Induction of robust B cell responses after influenza mRNA vaccination Is accompanied by circulating hemagglutinin-specific ICOS+ PD-1+ CXCR3+ T follicular helper cells

Lindgren, G., Ols, S., Liang, F., Thompson, E. A., Lin, A., Hellgren, F., Bahl, K., John, S., Yuzhakov, O., Hassett, K. J., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01539 · Cited by 132 · see citing works

Factors Which Contribute to the Immunogenicity of Non-replicating Adenoviral Vectored Vaccines

Coughlan, L. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00909 · Cited by 132 · see citing works

Role of Vector in Activation of T Cell Subsets in Immune Responses against the Secreted Transgene Product Factor IX

Fields, P. A., Kowalczyk, D. W., Arruda, V. R., Armstrong, E., McCleland, M. L., Hagstrom, J. N., Pasi, J., Ertl, H. C. J., Herzog, R. W., & High, K. A. (2000) · Molecular Therapy · doi:10.1006/mthe.2000.0032 · Cited by 129 · see citing works

Preferential Activation of Toll-Like Receptor Nine by CD46-Utilizing Adenoviruses

Iacobelli-Martinez, M., & Nemerow, G. R. (2006) · Journal of Virology · doi:10.1128/jvi.01926-06 · Cited by 113 · see citing works

Perspective on Adenoviruses: Epidemiology, Pathogenicity, and Gene Therapy

Crenshaw, B. J., Jones, L. B., Bell, C. R., Kumar, S., & Matthews, Q. L. (2019) · Biomedicines · doi:10.3390/biomedicines7030061 · Cited by 106 · see citing works

Catalytic activity of vaccinia mRNA capping enzyme subunits coexpressed in Escherichia coli.

Shuman, S. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)38494-7 · Cited by 102 · see citing works

Innate immune sensing of DNA viruses

Rathinam, V. A. K., & Fitzgerald, K. A. (2011) · Virology · doi:10.1016/j.virol.2011.02.003 · Cited by 102 · see citing works

M2e-immobilized gold nanoparticles as influenza A vaccine: Role of soluble M2e and longevity of protection

Tao, W., & Gill, H. S. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.03.063 · Cited by 99 · see citing works

Polymeric micro- and nanoparticles for immune modulation

Ben‐Akiva, E., Est-Witte, S. E., Meyer, R. A., Rhodes, K. R., & Green, J. J. (2018) · Biomaterials Science · doi:10.1039/c8bm01285g · Cited by 97 · see citing works

Production, Processing, and Characterization of Synthetic AAV Gene Therapy Vectors

Andari, J. E., & Grimm, D. (2020) · Biotechnology Journal · doi:10.1002/biot.202000025 · Cited by 97 · see citing works

Immune Evasion by Adenovirus E3 Proteins: Exploitation of Intracellular Trafficking Pathways

Windheim, M., Hilgendorf, A., & Burgert, H.-G. (2004) · Current topics in microbiology and immunology · doi:10.1007/978-3-662-05599-1_2 · Cited by 95 · see citing works

Tunable degradation of acetalated dextran microparticles enables controlled vaccine adjuvant and antigen delivery to modulate adaptive immune responses

Chen, N., Johnson, M. M., Collier, M. A., Gallovic, M. D., Bachelder, E. M., & Ainslie, K. M. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.01.027 · Cited by 88 · see citing works

Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study

Baden, L. R., Stieh, D. J., Sarnecki, M., Walsh, S. R., Tomaras, G. D., Kublin, J. G., McElrath, M. J., Alter, G., Ferrari, G., Montefiori, D. C., et al. (2020) · The Lancet HIV · doi:10.1016/s2352-3018(20)30229-0 · Cited by 88 · see citing works

Novel vaccine vectors for HIV-1

Barouch, D. H., & Picker, L. J. (2014) · Nature Reviews Microbiology · doi:10.1038/nrmicro3360 · Cited by 87 · see citing works

Overcoming challenges in treating autoimmuntity: Development of tolerogenic immune-modifying nanoparticles

Pearson, R. M., Podojil, J. R., Shea, L. D., King, N. J. C., Miller, S. D., & Getts, D. R. (2018) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2018.10.001 · Cited by 81 · see citing works

First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17 months old infants and children

Tiono, A. B., Nébié, I., Anagnostou, N. A., Coulibaly, A., Bowyer, G., Lam, E., Bougouma, E. C. C., Ouédraogo, A., Yaro, J. B., Barry, A., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0208328 · Cited by 79 · see citing works

Prevention of Maternal and Congenital Cytomegalovirus Infection

Johnson, J. M., Anderson, B., & Pass, R. F. (2012) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0b013e3182510b7b · Cited by 77 · see citing works

Engineering Immune Tolerance with Biomaterials

Gammon, J. M., & Jewell, C. M. (2019) · Advanced Healthcare Materials · doi:10.1002/adhm.201801419 · Cited by 77 · see citing works

Safety and Tolerability of Conserved Region Vaccines Vectored by Plasmid DNA, Simian Adenovirus and Modified Vaccinia Virus Ankara Administered to Human Immunodeficiency Virus Type 1-Uninfected Adults in a Randomized, Single-Blind Phase I Trial

Hayton, E., Rose, A., Ibrahimsa, U., Sorbo, M. D., Capone, S., Crook, A., Black, A. P., Dorrell, L., & Hanke, T. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101591 · Cited by 74 · see citing works

Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in adults in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial

Tapia, M. D., Sow, S. O., Ndiaye, B., Mbaye, K. D., Thiongane, A., N'Dour, C. T., Mboup, S., Ake, J. A., Keshinro, B., Akintunde, A., et al. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30016-5 · Cited by 74 · see citing works

New concepts in HIV-1 vaccine development

Stephenson, K. E., D’Couto, H. T., & Barouch, D. H. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.05.011 · Cited by 73 · see citing works

TLR-adjuvanted nanoparticle vaccines differentially influence the quality and longevity of responses to malaria antigen Pfs25

Thompson, E. A., Ols, S., Miura, K., Rausch, K. M., Narum, D. L., Spångberg, M., Juraska, M., Wille-Reece, U., Weiner, A. J., Howard, R. F., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.120692 · Cited by 73 · see citing works

Combining antigen and immunomodulators: Emerging trends in antigen-specific immunotherapy for autoimmunity

Northrup, L., Christopher, M. A., Sullivan, B. P., & Berkland, C. J. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.10.020 · Cited by 72 · see citing works

Prolonged evolution of the memory B cell response induced by a replicating adenovirus-influenza H5 vaccine

Matsuda, K., Huang, J., Zhou, T., Sheng, Z., Kang, B. H., Ishida, E., Griesman, T., Stuccio, S., Bolkhovitinov, L., Wohlbold, T. J., et al. (2019) · Science Immunology · doi:10.1126/sciimmunol.aau2710 · Cited by 70 · see citing works

Certifying the interruption of wild poliovirus transmission in the WHO African region on the turbulent journey to a polio-free world

Leke, R. G. F., King, A. S., Pallansch, M. A., Tangermann, R. H., Mkanda, P., Chunsuttiwat, S., Jack, A., KABORE, B., Kane, I., Khomo, N. E., et al. (2020) · The Lancet Global Health · doi:10.1016/s2214-109x(20)30382-x · Cited by 63 · see citing works

Heplisav-B: A Hepatitis B Vaccine With a Novel Adjuvant

Champion, C. R. (2020) · Annals of Pharmacotherapy · doi:10.1177/1060028020962050 · Cited by 63 · see citing works

Association of Use of a Meningococcus Group B Vaccine With Group B Invasive Meningococcal Disease Among Children in Portugal

Rodrigues, F. M. P., Marlow, R. D., Simões, M. J., Danon, L., Ladhani, S. N., & Finn, A. H. R. (2020) · JAMA · doi:10.1001/jama.2020.20449 · Cited by 63 · see citing works

Diversity within the adenovirus fiber knob hypervariable loops influences primary receptor interactions

Baker, A. T., Greenshields‐Watson, A., Coughlan, L., Davies, J. A., Uusi-Kerttula, H. K., Cole, D. K., Rizkallah, P. J., & Parker, A. L. (2019) · Nature Communications · doi:10.1038/s41467-019-08599-y · Cited by 62 · see citing works

Engineering self-assembled materials to study and direct immune function

Tostanoski, L. H., & Jewell, C. M. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.03.005 · Cited by 60 · see citing works

Viral vectors as vaccine carriers

Ertl, H. C. J. (2016) · Current Opinion in Virology · doi:10.1016/j.coviro.2016.06.001 · Cited by 59 · see citing works

Herpes Simplex Virus Vectors for Gene Transfer to the Central Nervous System

Artusi, S., Miyagawa, Y., Goins, W. F., Cohen, J. B., & Glorioso, J. C. (2018) · Diseases · doi:10.3390/diseases6030074 · Cited by 59 · see citing works

The old and the new: Prospects for non-integrating lentiviral vector technology

Apolonia, L. (2020) · Viruses · doi:10.3390/v12101103 · Cited by 58 · see citing works

A Chimpanzee-Origin Adenovirus Vector Expressing the Rabies Virus Glycoprotein as an Oral Vaccine against Inhalation Infection with Rabies Virus

Zhou, D., Cun, A., Li, Y., Xiang, Z., & Ertl, H. C. J. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.03.027 · Cited by 57 · see citing works

Particulate delivery systems for vaccination against bioterrorism agents and emerging infectious pathogens

Fan, Y., & Moon, J. J. (2016) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1403 · Cited by 46 · see citing works

Integrating Biomaterials and Immunology to Improve Vaccines Against Infectious Diseases

Yenkoidiok-Douti, L., & Jewell, C. M. (2020) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.9b01255 · Cited by 42 · see citing works

Rhesus Macaque Myeloid-Derived Suppressor Cells Demonstrate T Cell Inhibitory Functions and Are Transiently Increased after Vaccination

Lin, A., Liang, F., Thompson, E. A., Vono, M., Ols, S., Lindgren, G., Hassett, K. J., Salter, H., Ciaramella, G., & Loré, K. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1701005 · Cited by 41 · see citing works

Safety and Immunogenicity of Heterologous and Homologous 2-Dose Regimens of Adenovirus Serotype 26– and Modified Vaccinia Ankara–Vectored Ebola Vaccines: A Randomized, Controlled Phase 1 Study

Goldstein, N. H., Bockstal, V., Bart, S., Lühn, K., Robinson, C., Gaddah, A., Callendret, B., & Douoguih, M. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa586 · Cited by 40 · see citing works

A Novel Vaccine Strategy Employing Serologically Different Chimpanzee Adenoviral Vectors for the Prevention of HIV-1 and HCV Coinfection

Hartnell, F., Brown, A., Capone, S., Kopycinski, J. T., Bliss, C. M., Makvandi‐Nejad, S., Swadling, L., Ghaffari, E., Cicconi, P., Sorbo, M. D., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03175 · Cited by 36 · see citing works

Rapid Cloning of Novel Rhesus Adenoviral Vaccine Vectors

Abbink, P., Kirilova, M., Boyd, M. B., Mercado, N. B., Li, Z., Nityanandam, R., Nanayakkara, O., Peterson, R., Larocca, R. A., Aïd, M., et al. (2018) · Journal of Virology · doi:10.1128/jvi.01924-17 · Cited by 34 · see citing works

Adenovirus Vector-Based Vaccines Confer Maternal-Fetal Protection against Zika Virus Challenge in Pregnant IFN-αβR−/− Mice

Larocca, R. A., Mendes, É. A., Abbink, P., Peterson, R., Martinot, A. J., Iampietro, M. J., Kang, Z. H., Aïd, M., Kirilova, M., Jacob-Dolan, C., et al. (2019) · Cell Host & Microbe · doi:10.1016/j.chom.2019.10.001 · Cited by 31 · see citing works

Noncanonical Functions of Antibodies

Dimitrov, J. D., & Lacroix‐Desmazes, S. (2020) · Trends in Immunology · doi:10.1016/j.it.2020.03.006 · Cited by 30 · see citing works

Taxonomy proposal for Old World monkey adenoviruses: characterisation of several non-human, non-ape primate adenovirus lineages

Pantó, L., Podgorski, I. I., Jánoska, M., Márkó, O., & Balázs Harrach, B. (2015) · Archives of Virology · doi:10.1007/s00705-015-2575-z · Cited by 28 · see citing works

Recombinant zoster vaccine (Shingrix®): a new option for the prevention of herpes zoster and postherpetic neuralgia

Singh, G., Song, S.-J., Choi, E. J., Lee, P. B., & Nahm, F. S. (2020) · The Korean journal of pain · doi:10.3344/kjp.2020.33.3.201 · Cited by 24 · see citing works

Poxviruses as Gene Therapy Vectors: Generating Poxviral Vectors Expressing Therapeutic Transgenes

Conrad, S. J., & Liu, J. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9065-8_11 · Cited by 22 · see citing works

Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) and a preclinical study in rhesus monkeys (NHP 17–22)

Stephenson, K. E., Wegmann, F., Tomaka, F. L., Walsh, S. R., Tan, C. S., Lavreys, L., Ansel, J. L., Kanjilal, D. G., Jaegle, K., Nkolola, J. P., et al. (2020) · The Lancet HIV · doi:10.1016/s2352-3018(20)30001-1 · Cited by 22 · see citing works

Characterization of a Species E Adenovirus Vector as a Zika virus vaccine

Bullard, B. L., Corder, B. N., Gordon, D. N., Pierson, T. C., & Weaver, E. A. (2020) · Scientific Reports · doi:10.1038/s41598-020-60238-5 · Cited by 22 · see citing works

Adenovirus type 35-vectored tuberculosis vaccine has an acceptable safety and tolerability profile in healthy, BCG-vaccinated, QuantiFERON®-TB Gold (+) Kenyan adults without evidence of tuberculosis

Walsh, D. S., Owira, V., Polhemus, M. E., Otieno, L., Andagalu, B. M., Ogutu, B. R., Waitumbi, J. N., Hawkridge, A., Shepherd, B. M., Pau, M. G., et al. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.03.069 · Cited by 16 · see citing works

Implementation of accelerated research: strategies for implementation as applied in a phase 1 Ad26.ZEBOV, MVA-BN-Filo two-dose Ebola vaccine clinical trial in Uganda

Kitonsa, J., Ggayi, A.-B., Anywaine, Z., Kisaakye, E., Nsangi, L., Basajja, V., Nyantaro, M., Watson‐Jones, D., Shukarev, G., Ilsbroux, I., et al. (2020) · Global Health Action · doi:10.1080/16549716.2020.1829829 · Cited by 13 · see citing works

Immunogenicity and Cross-Reactivity of Rhesus Adenoviral Vectors

Iampietro, M. J., Larocca, R. A., Provine, N. M., Abbink, P., Kang, Z. H., Bricault, C. A., & Barouch, D. H. (2018) · Journal of Virology · doi:10.1128/jvi.00159-18 · Cited by 10 · see citing works

Lipid nanoparticles for mRNA delivery

Hou, X., Zaks, T., Langer, R., & Dong, Y. (2021) · Nature Reviews Materials · doi:10.1038/s41578-021-00358-0 · Cited by 4,076 · see citing works

Neoantigens: promising targets for cancer therapy

Xie, N., Shen, G., Gao, W., Huang, Z., Huang, C., & Fu, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01270-x · Cited by 1,020 · see citing works

Recent advances in regenerative biomaterials

Cao, D., & Ding, J. (2022) · Regenerative Biomaterials · doi:10.1093/rb/rbac098 · Cited by 274 · see citing works

Nanoparticle-Based Delivery Systems for Vaccines

Bezbaruah, R., Chavda, V. P., Nongrang, L., Alom, S., Deka, K., Kalita, T., Ali, F., Bhattacharjee, B., & Vora, L. K. (2022) · Vaccines · doi:10.3390/vaccines10111946 · Cited by 267 · see citing works

Lipid nanoparticles in the development of mRNA vaccines for COVID-19

Wilson, B., & Geetha, K. M. (2022) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2022.103553 · Cited by 257 · see citing works

Structural basis for enhanced infectivity and immune evasion of SARS-CoV-2 variants

Cai, Y., Zhang, J., Xiao, T., Lavine, C. L., Rawson, S., Peng, H., Zhu, H., Anand, K., Tong, P., Gautam, A. K., et al. (2021) · Science · doi:10.1126/science.abi9745 · Cited by 219 · see citing works

COVID-19 vaccination: The road ahead

Altmann, D. M., & Boyton, R. J. (2022) · Science · doi:10.1126/science.abn1755 · Cited by 195 · see citing works

Nanotechnology-based mRNA vaccines

Chen, S., Huang, X., Xue, Y., Álvarez‐Benedicto, E., Shi, Y., Chen, W., Koo, S., Siegwart, D. J., Dong, Y., & Tao, W. (2023) · Nature Reviews Methods Primers · doi:10.1038/s43586-023-00246-7 · Cited by 172 · see citing works

Synthetic Biology: Bottom-Up Assembly of Molecular Systems

Hirschi, S., Ward, T. R., Meier, W. P., Müller, D. J., & Fotiadis, D. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.2c00339 · Cited by 149 · see citing works

An aluminum hydroxide:CpG adjuvant enhances protection elicited by a SARS-CoV-2 receptor binding domain vaccine in aged mice

Nanishi, E., Borriello, F., O’Meara, T. R., McGrath, M. E., Saito, Y., Haupt, R. E., Seo, H., van Haren, S. D., Cavazzoni, C. B., Brook, B., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abj5305 · Cited by 122 · see citing works

DC-Derived Exosomes for Cancer Immunotherapy

Yao, Y., Fu, C., Zhou, L., Mi, Q., & Jiang, A. (2021) · Cancers · doi:10.3390/cancers13153667 · Cited by 115 · see citing works

Recent advances in lipid nanoparticles for delivery of nucleic acid, mRNA, and gene editing-based therapeutics

Mukai, H., Ogawa, K., Kato, N., & Kawakami, S. (2022) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2022.100450 · Cited by 108 · see citing works

Lipid nanoparticles: Composition, formulation, and application

Xu, S., Hu, Z., Song, F., Xu, Y. G., & Han, X. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101463 · Cited by 105 · see citing works

The advances of adjuvants in mRNA vaccines

Xie, C., Yao, R., & Xia, X. (2023) · npj Vaccines · doi:10.1038/s41541-023-00760-5 · Cited by 98 · see citing works

Arginine Supplementation Targeting Tumor-Killing Immune Cells Reconstructs the Tumor Microenvironment and Enhances the Antitumor Immune Response

Zhang, J., Wang, S., Guo, X., Lu, Y., Liu, X., Jiang, M., Li, X., Qin, B., Luo, Z., Liu, H., et al. (2022) · ACS Nano · doi:10.1021/acsnano.2c05408 · Cited by 85 · see citing works

Advanced technologies for the development of infectious disease vaccines

Gupta, A., Rudra, A., Reed, K., Langer, R., & Anderson, D. G. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01041-z · Cited by 85 · see citing works

Biomimetic Exosomes: A New Generation of Drug Delivery System

Wang, X., Zhao, X., Zhong, Y., Shen, J., & An, W. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.865682 · Cited by 79 · see citing works

Potentialities and Challenges of mRNA Vaccine in Cancer Immunotherapy

Duan, L.-J., Wang, Q., Zhang, C., Yang, D.-X., & Zhang, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.923647 · Cited by 79 · see citing works

COVID-19 Vaccines: Adenoviral Vectors

Jacob-Dolan, C., & Barouch, D. H. (2021) · Annual Review of Medicine · doi:10.1146/annurev-med-012621-102252 · Cited by 76 · see citing works

Engineered Cell Membrane‐Derived Nanoparticles in Immune Modulation

Yang, Y., Wang, K., Pan, Y., Rao, L., & Luo, G. (2021) · Advanced Science · doi:10.1002/advs.202102330 · Cited by 75 · see citing works

Advances in the polymeric delivery of nucleic acid vaccines

Chen, G., Zhao, B., Ruiz, E. F., & Zhang, F. (2022) · Theranostics · doi:10.7150/thno.70853 · Cited by 75 · see citing works

Vaccine Strategies to Elicit Mucosal Immunity

Song, Y., Mehl, F., & Zeichner, S. L. (2024) · Vaccines · doi:10.3390/vaccines12020191 · Cited by 80 · see citing works

Controversy surrounding the Sputnik V vaccine

Cazzola, M., Rogliani, P., Mazzeo, F., & Matera, M. G. (2021) · Respiratory Medicine · doi:10.1016/j.rmed.2021.106569 · Cited by 66 · see citing works

Adenovirus-based vaccines—a platform for pandemic preparedness against emerging viral pathogens

Coughlan, L., Kremer, E. J., & Shayakhmetov, D. M. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.01.034 · Cited by 66 · see citing works

Seasonal influenza vaccine performance and the potential benefits of mRNA vaccines

Russell, C. A., Fouchier, R. A. M., Ghaswalla, P. K., Park, Y., Vicic, N., Ananworanich, J., Nachbagauer, R., & Rudin, D. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2336357 · Cited by 69 · see citing works

Mannose in vaccine delivery

Nahar, U. J., Tóth, I., & Skwarczyński, M. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.09.038 · Cited by 64 · see citing works

Host Responses to Respiratory Syncytial Virus Infection

Agac, A., Kolbe, S. M., Ludlow, M., Osterhaus, A. D. M. E., Meineke, R., & Rimmelzwaan, G. F. (2023) · Viruses · doi:10.3390/v15101999 · Cited by 69 · see citing works

Realveolarization with inhalable mucus-penetrating lipid nanoparticles for the treatment of pulmonary fibrosis in mice

Wang, Y. X., Zhang, J., Liu, Y., Xiao, Y., Han, K. S., Kong, Z., Dong, Y., Yang, Z., Fu, Z., Tang, C., et al. (2024) · Science Advances · doi:10.1126/sciadv.ado4791 · Cited by 62 · see citing works

COVID-eVax, an electroporated DNA vaccine candidate encoding the SARS-CoV-2 RBD, elicits protective responses in animal models

Conforti, A., Marra, E., Palombo, F., Roscilli, G., Ravà, M., Fumagalli, V., Muzi, A., Maffei, M., Luberto, L., Lione, L., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.09.011 · Cited by 60 · see citing works

Bioengineered nanotechnology for nucleic acid delivery

Zhang, Y., Luo, J., Gui, X., Zheng, Y., Schaar, E., Liu, G., & Shi, J. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.10.034 · Cited by 61 · see citing works

Bacteria extracellular vesicle as nanopharmaceuticals for versatile biomedical potential

Ho, M. Y., Liu, S., & Xing, B. (2024) · Nano Convergence · doi:10.1186/s40580-024-00434-5 · Cited by 60 · see citing works

Emerging Trends in Lipid-Based Vaccine Delivery: A Special Focus on Developmental Strategies, Fabrication Methods, and Applications

Karunakaran, B., Gupta, R., Patel, P., Salave, S., Sharma, A. K., Desai, D. N., Benival, D. M., & Kommineni, N. (2023) · Vaccines · doi:10.3390/vaccines11030661 · Cited by 59 · see citing works

Current progress in the development of prophylactic and therapeutic vaccines

Li, T., Qian, C., Gu, Y., Zhang, J., Li, S., & Xia, N. (2022) · Science China Life Sciences · doi:10.1007/s11427-022-2230-4 · Cited by 57 · see citing works

Advances of mRNA vaccine in tumor: a maze of opportunities and challenges

Yuan, Y., Gao, F., Chang, Y., Zhao, Q., & He, X. (2023) · Biomarker Research · doi:10.1186/s40364-023-00449-w · Cited by 58 · see citing works

Components, Formulations, Deliveries, and Combinations of Tumor Vaccines

Liu, T., Yao, W., Sun, W., Yuan, Y., Liu, C., Liu, X., Wang, X., & Jiang, H. (2024) · ACS Nano · doi:10.1021/acsnano.4c05065 · Cited by 56 · see citing works

Rational development of a combined mRNA vaccine against COVID-19 and influenza

Ye, Q., Wu, M., Chao Hui, Z. H. O. U., Lu, X., Huang, B., Zhang, N., Zhao, H. J., Chi, H., Zhang, X., Ling, D., et al. (2022) · npj Vaccines · doi:10.1038/s41541-022-00478-w · Cited by 51 · see citing works

Bioresponsive Immunotherapeutic Materials

Han, J., Sheng, T., Zhang, Y., Cheng, H., Gao, J., Yu, J., & Gu, Z. (2023) · Advanced Materials · doi:10.1002/adma.202209778 · Cited by 51 · see citing works

An Update on mRNA-Based Viral Vaccines

Jeeva, S., Kim, K., Shin, C. H., Wang, B., & Kang, S. (2021) · Vaccines · doi:10.3390/vaccines9090965 · Cited by 49 · see citing works

Advances in lipid nanoparticle mRNA therapeutics beyond COVID-19 vaccines

Wu, Y., Yu, S., & de Lázaro, I. (2024) · Nanoscale · doi:10.1039/d4nr00019f · Cited by 50 · see citing works

Stabilization of the SARS-CoV-2 Spike Receptor-Binding Domain Using Deep Mutational Scanning and Structure-Based Design

Ellis, D., Brunette, N., Crawford, K. H. D., Walls, A. C., Pham, M. N., Chen, C., Herpoldt, K., Fiala, B., Murphy, M., Pettie, D., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.710263 · Cited by 45 · see citing works

A Polyvalent Peptide CD40 Nanoagonist for Targeted Modulation of Dendritic Cells and Amplified Cancer Immunotherapy

Mamuti, M., Wang, Y., Zhao, Y., Wang, J., Wang, J., Fan, Y., Xiao, W., Hou, D., Yang, J., Zheng, R., et al. (2022) · Advanced Materials · doi:10.1002/adma.202109432 · Cited by 49 · see citing works

Development of Nasal Vaccines and the Associated Challenges

Nian, X., Zhang, J., Huang, S., Duan, K., Li, X., & Yang, X. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14101983 · Cited by 48 · see citing works

Mesenchymal stem cell-based treatments for COVID-19: status and future perspectives for clinical applications

Chen, L., Qu, J., Kalyani, F. S., Zhang, Q., Fan, L., Fang, Y., Li, Y., & Xiang, C. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-04096-y · Cited by 45 · see citing works

Scope and challenges of nanoparticle-based mRNA delivery in cancer treatment

Karim, M. E., Haque, S. T., Al-Busaidi, H., Bakhtiar, A., Tha, K. K., Holl, M. M. B., & Chowdhury, E. H. (2022) · Archives of Pharmacal Research · doi:10.1007/s12272-022-01418-x · Cited by 42 · see citing works

In Silico Studies to Support Vaccine Development

Saldanha, L., Langel, Ü., & Vale, N. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020654 · Cited by 41 · see citing works

COVID-19 vaccines: Immune correlates and clinical outcomes

Mahrokhian, S. H., Tostanoski, L. H., Vidal, S. J., & Barouch, D. H. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2324549 · Cited by 40 · see citing works

Autoimmune hepatitis after COVID-19 vaccination

Han, Z., Zhang, T., Xu, Y., Lu, X. B., & Sang, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1035073 · Cited by 38 · see citing works

Vaccines against extraintestinal pathogenic Escherichia coli (ExPEC): progress and challenges

Qiu, L., Chirman, D. M., Clark, J. R., Xing, Y., Santos, H. H., Vaughan, E. E., & Maresso, A. W. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2359691 · Cited by 38 · see citing works

SARS-CoV-2 infections elicit higher levels of original antigenic sin antibodies compared with SARS-CoV-2 mRNA vaccinations

Anderson, E. M., Li, S. H., Awofolaju, M., Eilola, T., Goodwin, E. C., Bolton, M. J., Gouma, S., Manzoni, T. B., Hicks, P. D., Goel, R. R., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111496 · Cited by 35 · see citing works

Lipid-based colloidal nanoparticles for applications in targeted vaccine delivery

Khan, M. S., Appak‐Baskoy, S., Yang, C. J., Hong, J., Chae, J., Ha, H.-J., Lee, S., Tanaka, M., Choi, Y., & Choi, J. H. (2023) · Nanoscale Advances · doi:10.1039/d2na00795a · Cited by 37 · see citing works

Umbilical artery acid-base status in the preterm infant.

Ramin, S. M., Gilstrap, L. C., Leveno, K. J., Burris, J., & Little, “. B. B. (1989) · PubMed · Cited by 37 · see citing works

Analytical Characterization of Heterogeneities in mRNA-Lipid Nanoparticles Using Sucrose Density Gradient Ultracentrifugation

Vaidya, A. M., Parande, D., Khadse, N., Vargas‐Montoya, N., Agarwal, V., Ortiz, C., Ellis, G., Kaushal, N., Sarode, A., Karve, S., et al. (2024) · Analytical Chemistry · doi:10.1021/acs.analchem.4c00031 · Cited by 34 · see citing works

Vaccine innovation model: A technology transfer perspective in pandemic contexts

Medeiros, M. Z., Soares, P. F., Fialho, B. D. C., Gauss, L., Piran, F. S., & Lacerda, D. P. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.06.054 · Cited by 33 · see citing works

Zwitterionic materials for nucleic acid delivery and therapeutic applications

He, S., & Liu, S. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.12.017 · Cited by 33 · see citing works

Vaccine development using artificial intelligence and machine learning: A review

Asediya, V., Anjaria, P. A., Mathakiya, R. A., KORINGA, P. G., Nayak, J. B., Bisht, D., Fulmali, D., Patel, V. A., & Desai, D. N. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.136643 · Cited by 35 · see citing works

Nanovaccines against Animal Pathogens: The Latest Findings

Celis-Giraldo, C. T., López‐Abán, J., Muro, A., Patarroyo, M. A., & Manzano-Román, R. (2021) · Vaccines · doi:10.3390/vaccines9090988 · Cited by 33 · see citing works

Enhancing Skin Cancer Immunotheranostics and Precision Medicine through Functionalized Nanomodulators and Nanosensors: Recent Development and Prospects

Farhana, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043493 · Cited by 32 · see citing works

In silico designed novel multi-epitope mRNA vaccines against Brucella by targeting extracellular protein BtuB and LptD

Shi, J., Zhu, Y., Yin, Z., He, Y., Li, Y., Haimiti, G., Xie, X., Niu, C., Guo, W., & Zhang, F. (2024) · Scientific Reports · doi:10.1038/s41598-024-57793-6 · Cited by 34 · see citing works

mRNA vaccines induce rapid antibody responses in mice

Gebre, M. S., Rauch, S., Roth, N., Gergen, J., Yu, J., Liu, X., Cole, A. C., Mueller, S. O., Petsch, B., & Barouch, D. H. (2022) · npj Vaccines · doi:10.1038/s41541-022-00511-y · Cited by 32 · see citing works

Vaccination Strategies Based on Bacterial Self-Assembling Proteins as Antigen Delivery Nanoscaffolds

Lamontagne, F., Khatri, V., St‐Louis, P., Bourgault, S., & Archambault, D. (2022) · Vaccines · doi:10.3390/vaccines10111920 · Cited by 32 · see citing works

mRNA COVID-19 Vaccines—Facts and Hypotheses on Fragmentation and Encapsulation

Jacques Demongeot, A., & Fougère, C. (2022) · Vaccines · doi:10.3390/vaccines11010040 · Cited by 35 · see citing works

Nanoparticles and Antiviral Vaccines

Liu, S., Hu, M., Liu, X., Liu, X., Chen, T., Zhu, Y., Liang, T., Xiao, S., Li, P., & Ma, X. (2023) · Vaccines · doi:10.3390/vaccines12010030 · Cited by 33 · see citing works

Viral vector- and virus-like particle-based vaccines against infectious diseases: A minireview

Henríquez, R., & Muñoz‐Barroso, I. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e34927 · Cited by 31 · see citing works

The impact of COVID-19 in pregnancy: Part II. Vaccination to pregnant women

Wang, P., Lee, W.-L., Yang, S., Tsui, K., Chang, C., & Lee, F. (2021) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000000612 · Cited by 31 · see citing works

Comparative immunogenicity of an mRNA/LNP and a DNA vaccine targeting HIV gag conserved elements in macaques

Valentin, A., Bergamaschi, C., Rosati, M., Angel, M., Burns, R., Agarwal, M., Gergen, J., Petsch, B., Oostvogels, L., Loeliger, E., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.945706 · Cited by 31 · see citing works

Path towards mRNA delivery for cancer immunotherapy from bench to bedside

Chen, W., Zhu, Y., He, J., & Sun, X. (2023) · Theranostics · doi:10.7150/thno.89247 · Cited by 31 · see citing works

Engineering nanoplatforms of bacterial outer membrane vesicles to overcome cancer therapy resistance

Chai, Q., Li, D., Zhang, M., Gu, Y., Li, A., Wu, X., Liu, X., & Liu, J. (2025) · Drug Resistance Updates · doi:10.1016/j.drup.2025.101277 · Cited by 30 · see citing works

Sustainable vaccine manufacturing in low- and middle-Income countries

Hayman, B., Suri, R. K., & Downham, M. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.10.044 · Cited by 30 · see citing works

mRNAs encoding self-DNA reactive cGAS enhance the immunogenicity of lipid nanoparticle vaccines

Zhivaki, D., Gosselin, E. A., Sengupta, D., Concepcion, H. A., Arinze, C., Chow, J., Nikiforov, A., Komoroski, V., MacFarlane, C., Sullivan, C., et al. (2023) · mBio · doi:10.1128/mbio.02506-23 · Cited by 29 · see citing works

Opportunities and challenges to implementing mRNA-based vaccines and medicines: lessons from COVID-19

Iqbal, S. M., Rosen, A. M., Edwards, D. K., Bolio, A., Larson, H. J., Servin, M., Rudowitz, M., Carfı́, A., & Ceddia, F. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1429265 · Cited by 28 · see citing works

Taylor Dispersion Analysis to support lipid-nanoparticle formulations for mRNA vaccines

Malburet, C., Leclercq, L., Cotte, J., Thiebaud, J., Bazin, E., Garinot, M., & Cottet, H. (2022) · Gene Therapy · doi:10.1038/s41434-022-00370-1 · Cited by 29 · see citing works

mRNA Vaccine Nanoplatforms and Innate Immunity

Wei, L., Dong, C., Zhu, W., & Wang, B. (2024) · Viruses · doi:10.3390/v16010120 · Cited by 28 · see citing works

Engineering customized nanovaccines for enhanced cancer immunotherapy

Guo, J., Liu, C., Qi, Z., Qiu, T., Zhang, J. C., & Yang, H. (2024) · Bioactive Materials · doi:10.1016/j.bioactmat.2024.02.028 · Cited by 27 · see citing works

Vaccine design and development: Exploring the interface with computational biology and AI

Ananya, A., Panchariya, D. C., Karthic, A., Singh, S. P., Mani, A., Chawade, A., & Kushwaha, S. K. (2024) · International Reviews of Immunology · doi:10.1080/08830185.2024.2374546 · Cited by 27 · see citing works

Advances in mRNA vaccines

Li, M., Wang, Z., Xie, C., & Xia, X. (2022) · International review of cytology · doi:10.1016/bs.ircmb.2022.04.011 · Cited by 30 · see citing works

Expanding the Potential of Circular RNA (CircRNA) Vaccines: A Promising Therapeutic Approach

Bu, T., Yang, W., Zhao, J., Gao, Y., Li, F., & Yang, R. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26010379 · Cited by 30 · see citing works

Breast cancer vaccines for treatment and prevention

Disis, M. L., & Cecil, D. L. (2021) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06459-2 · Cited by 26 · see citing works

An Adenovirus‐Mimicking Photoactive Nanomachine Preferentially Invades and Destroys Cancer Cells through Hijacking Cellular Glucose Metabolism

Zhang, Y., Feng, S., Hu, G., Fang, T., Xie, D., Lu, Q., Xu, Y., Shen, L., & Ning, X. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202110092 · Cited by 26 · see citing works

Supramolecular biomaterials for enhanced cancer immunotherapy

Zhang, H., Zhu, J., Fang, T., Li, M., Chen, G., & Chen, Q. (2022) · Journal of Materials Chemistry B · doi:10.1039/d2tb00048b · Cited by 26 · see citing works

Roles of RNA-binding proteins in neurological disorders, COVID-19, and cancer

Sanya, D. R. A., Cava, C., & Onésime, D. (2022) · Human Cell · doi:10.1007/s13577-022-00843-w · Cited by 26 · see citing works

Exosome may be the next generation of promising cell-free vaccines

Dai, Z., Cai, R., Zeng, H., Zhu, H., Dou, Y., & Sun, S. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2345940 · Cited by 25 · see citing works

Immune dynamics shaping pre-metastatic and metastatic niches in liver metastases: from molecular mechanisms to therapeutic strategies

Zhu, C., Liao, J.-Y., Liu, Y., Chen, Z., Chang, R.-Z., Chen, X., Zhang, B., & Liang, J.-N. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02171-z · Cited by 26 · see citing works

Vaccine Strategies Against RNA Viruses: Current Advances and Future Directions

Hsiung, K. C., Chiang, H.-J., Reinig, S., & Shih, S. (2024) · Vaccines · doi:10.3390/vaccines12121345 · Cited by 25 · see citing works

A tale of nucleic acid–ionizable lipid nanoparticles: Design and manufacturing technology and advancement

De, A., & Ko, Y. T. (2022) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2023.2153832 · Cited by 23 · see citing works

Vaccines and monoclonal antibodies to prevent healthcare-associated bacterial infections

Sauvat, L., Verhoeven, P., Gagnaire, J., Berthelot, P., Paul, S., Botelho-Nevers, E., & Gagneux-Brunon, A. (2024) · Clinical Microbiology Reviews · doi:10.1128/cmr.00160-22 · Cited by 22 · see citing works

Microfluidics for Nanomedicine Delivery

Chen, K., Yang, H., & Cai, R. (2025) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.4c02052 · Cited by 22 · see citing works

Use of Bacterial Extracellular Vesicles for Gene Delivery to Host Cells

Kim, S.-I., Ha, J. Y., Choi, S., Hong, S., & Lee, H. (2022) · Biomolecules · doi:10.3390/biom12091171 · Cited by 22 · see citing works

3D DNA origami pincers that multitask on giant unilamellar vesicles

Zhan, P., Yang, J., Ding, L. L., Jing, X., Hipp, K., Nußberger, S., Yan, H., & Liu, N. (2024) · Science Advances · doi:10.1126/sciadv.adn8903 · Cited by 21 · see citing works

Advances in the study of LNPs for mRNA delivery and clinical applications

Wang, B., Shen, B., Xiang, W., & Shen, H. (2024) · Virus Genes · doi:10.1007/s11262-024-02102-6 · Cited by 21 · see citing works

TransMA: an explainable multi-modal deep learning model for predicting properties of ionizable lipid nanoparticles in mRNA delivery

Wu, K., Wang, Z., Yang, X., Chen, Y., Mastrogiovanni, F., Zhang, J., & Liu, L. (2025) · Briefings in Bioinformatics · doi:10.1093/bib/bbaf307 · Cited by 21 · see citing works

Insights into the Novel Therapeutics and Vaccines against Herpes Simplex Virus

Malik, S., Sah, R., Ahsan, O., Muhammad, K., & Waheed, Y. (2023) · Vaccines · doi:10.3390/vaccines11020325 · Cited by 21 · see citing works

Vaccines as Potential Frontliners Against Antimicrobial Resistance (AMR): A Focused Review

Patil, S., Singh, I. P., Verma, I. K., Kumar, A., Sharma, J., Ratn, A., Dhakad, M. S., & Sharma, D. (2025) · Infection and Drug Resistance · doi:10.2147/idr.s544665 · Cited by 20 · see citing works

Immunotherapy-based novel nanoparticles in the treatment of gastrointestinal cancer: Trends and challenges

Ding, Y., Xue, M., Tang, Q., Wang, L., Ding, H.-Y., Li, H., Gao, C., & Yu, W. (2022) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i37.5403 · Cited by 20 · see citing works

Vetinformatics from functional genomics to drug discovery: Insights into decoding complex molecular mechanisms of livestock systems in veterinary science

Pathak, R. K., & Kim, J. (2022) · Frontiers in Veterinary Science · doi:10.3389/fvets.2022.1008728 · Cited by 20 · see citing works

Lipid-mRNA nanoparticles landscape for cancer therapy

Li, Y., Fang, H., Zhang, T., Wang, Y., Qi, T., Li, B., & Jiao, H. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.1053197 · Cited by 19 · see citing works

A China-developed adenovirus vector-based COVID-19 vaccine: review of the development and application of Ad5-nCov

Wang, S., Liu, W.-Q., Li, Y., Li, J., & Zhu, F. (2023) · Expert Review of Vaccines · doi:10.1080/14760584.2023.2242528 · Cited by 18 · see citing works

Outlining recent updates on influenza therapeutics and vaccines: A comprehensive review

Malik, S., Asghar, M., & Waheed, Y. (2024) · Vaccine X · doi:10.1016/j.jvacx.2024.100452 · Cited by 19 · see citing works

Recent development of oral vaccines (Review)

Liu, Y., Lam, D. M., Luan, M., Zheng, W., & Ai, H. (2024) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2024.12511 · Cited by 18 · see citing works

Exploring the immuno-nano nexus: A paradigm shift in tumor vaccines

Li, Y., Xu, Y., Su, W., Xu, J., Ye, Z., Wang, Z., Liu, Q., & Chen, F. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.117897 · Cited by 18 · see citing works

A Review on Novel Approaches in Vaccine Development

Shaikh Mujeeb Ur Rahman, A. Q. Q. *. (2025) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.15779378

Emerging Concepts and Technologies in Vaccine Development

Brisse, M. E., Vrba, S. M., Kirk, N. M., Liang, Y., & Ly, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.583077 · Cited by 325 · see citing works

Advances in Vaccine Development: A Comprehensive Review of Technological Progress and Challenges

Yan, N. (2024) · Theoretical and Natural Science · doi:10.54254/2753-8818/61/20241449

Vaccine development: Current trends and technologies

Poria, R., Kala, D., Nagraik, R., Walia, Y., Dhir, S., Singh, B., Kaushik, N. K., Noorani, M. S., Kaushal, A., & Gupta, S. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.122331 · Cited by 83 · see citing works

CURRENT PERSPECTIVES IN VACCINE DEVELOPMENT: A COMPREHENSIVE REVIEW

Nikam, D., Kulkarni, S., Yadav, V., & Pawar, A. (2026) · Iterative International Publishers eBooks · doi:10.58532/nbennurfmpiv6b1c23